Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-023501
Filing Date
2021-05-05
Accepted
2021-05-04 18:32:34
Documents
70
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q rare-10q_20210331.htm   iXBRL 10-Q 2657730
2 EX-10.1 rare-ex101_180.htm EX-10.1 57388
3 EX-31.1 rare-ex311_6.htm EX-31.1 21443
4 EX-31.2 rare-ex312_7.htm EX-31.2 21442
5 EX-32.1 rare-ex321_8.htm EX-32.1 11630
6 GRAPHIC gjr4y1al5cqt000001.jpg GRAPHIC 112879
  Complete submission text file 0001564590-21-023501.txt   8884510

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA rare-20210331.xsd EX-101.SCH 66237
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE rare-20210331_cal.xml EX-101.CAL 51136
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rare-20210331_def.xml EX-101.DEF 183645
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE rare-20210331_lab.xml EX-101.LAB 394668
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rare-20210331_pre.xml EX-101.PRE 316343
12 EXTRACTED XBRL INSTANCE DOCUMENT rare-10q_20210331_htm.xml XML 1569805
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

EIN.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36276 | Film No.: 21890374
SIC: 2834 Pharmaceutical Preparations